Skip to main content
TEYI PHARMACEUTICAL GROUP CO.,LTD logo

TEYI PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002728 ISIN · CNE100001WK6 LEI · 300300ZUIZCFPGQWOZ61 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,596 across all filing types
Latest filing 2021-04-20 AGM Information
Country CN China
Listing Shenzhen Stock Exchange 002728

About TEYI PHARMACEUTICAL GROUP CO.,LTD

https://www.tczy.com.cn

TEYI PHARMACEUTICAL GROUP CO.,LTD. specializes in the research, development, manufacturing, and distribution of pharmaceutical products. The company's portfolio primarily consists of Chinese patent medicines and chemical drug preparations. Its flagship product, Zhike Bao Tablets, is widely recognized for treating chronic bronchitis and cough-related ailments. Beyond respiratory health, the group produces a diverse range of medications covering cardiovascular diseases, gastrointestinal disorders, and anti-infective treatments. Teyi Pharmaceutical operates modern production facilities and maintains a robust distribution network to serve healthcare providers and pharmacies. The company emphasizes the integration of traditional medicinal knowledge with modern pharmaceutical technology to enhance product efficacy and safety.

Recent filings

Filing Released Lang Actions
年度股东大会通知
AGM Information Classification · 95% confidence The document is a detailed notice about the convening of the 2020 Annual General Meeting (AGM) of 特一药业集团股份有限公司, including the meeting date, agenda items, voting procedures, and proxy forms. It does not contain the actual annual report or financial statements but rather the notification and procedural information for the AGM. The document length is about 5203 characters, which is consistent with a detailed meeting notice rather than a full annual report. The content focuses on the announcement and arrangements for the AGM, including voting instructions and agenda proposals, which fits the definition of AGM Information (AGM-R).
2021-04-20 Chinese
2020年年度报告
Annual Report Classification · 100% confidence The document is titled '2020 年年度报告' which translates to '2020 Annual Report' and is issued by TEYI Pharmaceutical Group Co., Ltd. It contains detailed sections including company overview, financial data, business summary, management discussion and analysis, governance, and audited financial statements. The document covers the full fiscal year 2020 (January 1 to December 31) and includes comprehensive financial performance data, business operations, and management commentary. The length is substantial (15,000 characters), indicating it is the full report rather than a brief announcement. The presence of audited financial data and detailed analysis confirms it is the official yearly report covering company activity and full financial performance, consistent with the definition of an Annual Report (10-K). FY 2020
2021-04-20 Chinese
独立董事年度述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Director's Work Report" for the year 2020 by an independent director of a listed company. It details the director's attendance at board meetings, opinions on various company matters, committee work, investigations, supervision of information disclosure, governance structure, and suggestions for the company. It is a narrative report on the director's activities and oversight during the year, not a financial report or regulatory filing. It is not an announcement or a brief notice but a detailed report on management/board activities and governance oversight. This fits best under Board/Management Information (MANG) as it relates to the independent director's report on board activities and governance roles.
2021-04-20 Chinese
独立董事关于相关事项的事前认可意见
Board/Management Information Classification · 95% confidence The document is a statement from independent directors providing prior approval opinions regarding the extension of the validity period of a 2020 non-public stock issuance resolution and related authorizations. It references compliance with listing rules and company articles but does not contain financial data or detailed report content. The document is short (626 characters) and serves as an official opinion or announcement related to board matters, specifically about authorization and approval of capital issuance activities. This fits best under Board/Management Information (MANG) because it concerns board-level decisions and approvals rather than the actual capital issuance update or financial report. It is not a full capital/financing update (CAP) since it does not provide details of the financing itself, only the board's approval opinion. Therefore, the classification is MANG with high confidence.
2021-04-20 Chinese
2020年年度股东大会资料
AGM Information Classification · 95% confidence The document is titled as "2020 年年度股东大会资料" which translates to "2020 Annual General Meeting materials." It contains detailed reports and proposals to be presented and discussed at the 2020 Annual General Meeting (AGM) of the company, including the Board of Directors' work report, Supervisory Board report, financial statements, profit distribution plan, and other agenda items. The content is structured as materials prepared for the AGM, including detailed agenda items and reports to be reviewed by shareholders. There is no indication that this is the full annual report itself or a simple announcement of a report publication. Instead, it is the set of materials shared during the AGM. Therefore, the document fits the category of AGM Information (AGM-R). The document length and detail also support this classification with high confidence.
2021-04-20 Chinese
董事会决议公告
Board/Management Information Classification · 95% confidence The document is a detailed announcement of resolutions passed at the 16th meeting of the 4th Board of Directors of 特一药业集团股份有限公司, held on April 20, 2021. It includes approvals of the 2020 Board work report, 2020 General Manager work report, 2020 financial statements, profit distribution plan, internal control self-evaluation report, and other corporate governance matters. The document repeatedly states that these resolutions will be submitted to the shareholders' meeting for approval. The content is focused on board meeting decisions rather than the full annual report itself. The document length is 2398 characters, which is relatively short and more consistent with a board meeting resolution announcement rather than a full Annual Report (10-K). It is not a simple announcement of report publication but a detailed meeting resolution document. Therefore, the best fitting category is Board/Management Information (MANG), as it announces board meeting resolutions and management decisions.
2021-04-20 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.